See Tai Sandi
Chief Development Officer
See Tai Sandi has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Nov 20, 2025.
On the most recent filing, See Tai Sandi is listed as Chief Development Officer at Lexeo Therapeutics, Inc. Inside the rolling window, See Tai Sandi reported no open-market purchases and 2 open-market sales totaling $38K in LXEO. The largest disclosed transaction in the window is a sale of 3,888 LXEO shares on Oct 17, 2025, worth $35K.
Companies traded
Other insiders at LXEO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$38K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has See Tai Sandi made?
See Tai Sandi has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company since 2025.
Which companies does See Tai Sandi trade?
See Tai Sandi has filed SEC Form 4 disclosures for 1 company, including LXEO.
When was See Tai Sandi's most recent SEC Form 4 filing?
See Tai Sandi's most recent SEC Form 4 filing on Tracefour is dated Nov 20, 2025.
What is See Tai Sandi's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, See Tai Sandi is listed as Chief Development Officer.
What is See Tai Sandi's total buy and sell value in the current window?
Inside the rolling retention window, See Tai Sandi bought $0 and sold $38K based on SEC Form 4 filings.
What was See Tai Sandi's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 3,888 LXEO shares on 2025-10-17, worth $35K, per SEC Form 4 filings.